한글목차

2024년에는 전 세계 16개국에서 36,000건 이상의 국소분절사구체경화증(FSGS) 진단 사례가 발생할 것으로 예측됩니다. 현재 시장은 증상 치료에 사용되는 약물의 적응증 외 사용에만 대응하고 있어, 질병을 조절하고 효과적인 치료를 위한 시장에는 큰 격차가 존재합니다.

FSGS의 파이프라인에는 22개의 분자가 있습니다. 3상 파이프라인은 3종의 약물로 구성되어 있으며, 그 다음 5종의 2상 약물이 있습니다. 지난 10년 동안 미국은 FSGS의 임상시험 시설이 가장 많은 곳으로 500개가 넘었습니다. 지난 10년간 북미에서는 인수가 주류를 이루었습니다. 유럽에서는 라이선스 계약이 가장 많습니다.

이 보고서는 전 세계 국소분절사구체경화증(FSGS) 시장에 대해 조사했으며, 질환 개요와 함께 임상시험 동향, 파이프라인 개요, 향후 전망 등의 정보를 제공합니다.

목차

제1장 서문

제2장 주요 조사 결과

제3장 질병 상황

• 질환 개요
• 역학 개요
• 치료 개요

제4장 출시 약제 평가

• 주요 시판약
• 작용기서별 개요
• 분자 유형별 개요
• 제품 프로파일과 매출 예측

제5장 가격 설정과 상환 평가

• 연간 치료비
• 가격 설정과 상환까지 시간

제6장 파이프라인 약제 평가

• 중기에서 후기 단계 파이프라인 약제
• 개발 단계별 개요
• 작용기서별 개요
• 분자 유형별 개요
• 약제 고유의 상전이 성공률(PTSR)과 승인 가능성(LoA)
• 치료 분야와 적응증별 PTSR과 LoA

제7장 임상시험 평가

• 실적 개요
• 상별 개요
• 상황별 개요
• 진행중 및 계획중인 시험의 상별 개요
• 가상 컴포넌트 시험
• 지역의 시험 개요
• 지역별 단일국 및 다국간 시험
• 상별 스폰서 상위 20개사
• 상황별 스폰서 상위 20개사
• 엔드포인트 상황별 개요
• 인종과 민족별 개요
• 등록 데이터
• 임상시험 실시 시설 상위 20개국
• 세계의 상위 20개 사이트
• 실현 가능성 분석 - 지역적 개요
• 실현 가능성 분석 - 벤치마크 모델

제8장 거래 상황

제9장 상업적 평가

• 주요 시장 진출 기업

제10장 향후 시장 성장 촉진요인

제11장 부록

영문목차

This reports provides a data-driven overview of the current and future competitive landscape in Focal Segmental Glomerulosclerosis therapeutics.

• In 2024, more than 36,000 diagnosed incident cases of FSGS are anticipated in the 16 countries covered in GlobalData's epidemiology forecast for FSGS.
• There's a significant gap in the market for disease modifying and effective treatment as the current market is catered by only the off-label usage of drugs for symptomatic treatment.
• There are 22 molecules in the pipeline for FSGS. The Phase III pipeline consists of three drugs, followed by five drugs in Phase II.
• Over the past 10 years, the US has hosted the highest number of trial sites for FSGS, at more than 500 trial sites.
• In past decade, acquisitions were the predominant type of deal in North America. In Europe, licensing agreements were most frequent deal type.

Scope

GlobalData's Focal Segmental Glomerulosclerosis: Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

Components of the report include -

• Disease Landscape
• Disease Overview
• Epidemiology Overview
• Treatment Overview
• Marketed Products Assessment
• Breakdown by Mechanism of Action, Route of Administration
• Product Profiles with Sales Forecast
• Pricing and Reimbursement Assessment
• Annual Therapy Cost
• Time to Pricing and Time to Reimbursement
• Pipeline Assessment
• Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
• Product Profiles with Sales Forecast
• Late-to-mid-stage Pipeline Drugs
• Phase Transition Success Rate and Likelihood of Approval
• Clinical Trials Assessment
• Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
• Enrolment Analytics, Site Analytics, Feasibility Analysis
• Deals Landscape
• Mergers, Acquisitions, and Strategic Alliances by Region
• Overview of Recent Deals
• Commercial Assessment
• Key Market Players
• Future Market Catalysts

Reasons to Buy

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the Focal Segmental Glomerulosclerosis market.
• Drive revenues by understanding the key trends, innovative products and technologies, and companies likely to impact the global Focal Segmental Glomerulosclerosis market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories that present the maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1 Preface

• 1.1 Contents
• 1.2 Report Scope
• 1.3 List of Tables and Figures
• 1.4 Abbreviations

2 Key Findings

3 Disease Landscape

• 3.1 Disease Overview
• 3.2 Epidemiology Overview
• 3.3 Treatment Overview

4 Marketed Drugs Assessment

• 4.1 Leading Marketed Drugs
• 4.2 Overview by Mechanism of Action
• 4.3 Overview by Molecule Type
• 4.4 Product Profiles and Sales Forecast

5 Pricing and Reimbursement Assessment

• 5.1 Annual Cost of Therapy
• 5.2 Time to Pricing and Reimbursement

6 Pipeline Drugs Assessment

• 6.1 Mid-to-late-stage Pipeline Drugs
• 6.2 Overview by Development Stage
• 6.3 Overview by Mechanism of Action
• 6.4 Overview by Molecule Type
• 6.5 Drug Specific Phase Transition Success Rate (PTSR) and Likelihood of Approval (LoA)
• 6.6 Therapy Area and Indication-specific PTSR and LoA

7 Clinical Trials Assessment

• 7.1 Historical Overview
• 7.2 Overview by Phase
• 7.3 Overview by Status
• 7.4 Overview by Phase for Ongoing and Planned Trials
• 7.5 Trials with Virtual Components
• 7.6 Overview of Trials by Geography
• 7.7 Single-Country and Multinational Trials by Region
• 7.8 Top 20 Sponsors with Breakdown by Phase
• 7.9 Top 20 Sponsors with Breakdown by Status
• 7.10 Overview by Endpoint Status
• 7.11 Overview by Race and Ethnicity
• 7.12 Enrollment Data
• 7.13 Top 20 countries for Trial Sites
• 7.14 Top 20 Sites Globally
• 7.15 Feasibility Analysis - Geographic Overview
• 7.16 Feasibility Analysis - Benchmark Models

8 Deals Landscape

• 8.1 Mergers, Acquisitions, and Strategic Alliances by Region
• 8.2 Recent Mergers, Acquisitions, and Strategic Alliances

9 Commercial Assessment

• 9.1 Key Market Players

10 Future Market Catalysts

11 Appendix

• 11.1 Methodology
• 11.2 Methodology - Sales Forecast
• 11.3 Methodology - Pricing and Reimbursement
• 11.4 Methodology - PTSR and LoA Analysis
• 11.5 About the Authors
• 11.6 Contact Us
• 11.7 Disclaimer